Ingredient Intel File · sample
This is what your Ingredient Intel File looks like.
AI indexes 18,844+ trial records — updated weekly. Quality controls validate sources and consistency, with human review where risk requires. You receive a citable Intel File with honest evidence grades, including null results. Every paid file follows this structure.
01 · Executive Verdict
Reishi is commercially attractive and culturally legible in both Eastern and Western markets. The strongest supported use is immune wellness, stress resilience, and tradition-plus-evidence positioning R1, R2, R3. Evidence does not support lifespan extension no supporting human RCT or cancer treatment claims 2016 Cochrane — insufficient evidence. Claim language should stay conservative and steer clear of disease endpoints.
02 · Evidence Posture
Where this ingredient sits in the evidence landscape.
Evidence tier
29 human RCTs and 17 meta-analyses indexed. Strongest evidence is for immune modulation (Grade A). Lifespan claims have no human RCT support.
Evidence distribution
Key evidence landmark
2016 Cochrane review found insufficient evidence for Reishi as cancer treatment adjunct. Subsequent RCTs (2018–2024) strengthened immune modulation evidence to Grade A. No human RCT has tested lifespan extension claims.
03 · Claim Matrix
Outcome-by-outcome evidence breakdown.
Grade A = multiple high-quality RCTs, consistent effect. B = moderate evidence, effect size varies. C = weak / mixed. D = no human RCT support.
04 · Dosage & Safety
What the trials actually used — and where the safety signals are.
Safety signals
05 · Competitive Landscape
What others claim — and where the gaps are.
Claim language recommendation
“Supports immune function” — Grade A evidence, potentially supportable as a structure/function or general wellness claim; subject to jurisdiction, formulation, dosage, and regulatory review. Avoid “boosts immunity” (regulatory risk), “fights cancer” (prohibited), and “extends lifespan” (no human RCT). East market: “扶正固本” language may be supported by TCM category approval in relevant jurisdictions; consult regulatory counsel for specific product claims.
06 · Supplier Audit & Sources
What to verify before committing to a supplier.
Supplier audit checklist
Clinical trials (ClinicalTrials.gov)
Peer-reviewed literature (PubMed)
Every conclusion above links to a numbered source (R#) in this appendix. Informational only — an Intel File is not medical, legal, or regulatory advice; it is an evidence review to support your professional decision process.
Generate yours
Your ingredient. Your Intel File.
Submit one ingredient or claim. AI indexes and grades the evidence, quality controls validate it, Intel File delivered in 7 days. Starting at $799 — scope confirmed before payment.